Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Linz, D; Andrade, JG; Arbelo, E; Boriani, G; Breithardt, G; Camm, AJ; Caso, V; Nielsen, JC; De, Melis, M; De, Potter, T; Dichtl, W; Diederichsen, SZ; Dobrev, D; Doll, N; Duncker, D; Dworatzek, E; Eckardt, L; Eisert, C; Fabritz, L; Farkowski, M; Filgueiras-Rama, D; Goette, A; Guasch, E; Hack, G; Hatem, S; Haeusler, KG; Healey, JS; Heidbuechel, H; Hijazi, Z; Hofmeister, LH; Hove-Madsen, L; Huebner, T; Kääb, S; Kotecha, D; Malaczynska-Rajpold, K; Merino, JL; Metzner, A; Mont, L; Ng, GA; Oeff, M; Parwani, AS; Puererfellner, H; Ravens, U; Rienstra, M; Sanders, P; Scherr, D; Schnabel, R; Schotten, U; Sohns, C; Steinbeck, G; Steven, D; Toennis, T; Tzeis, S; van, Gelder, IC; van, Leerdam, RH; Vernooy, K; Wadhwa, M; Wakili, R; Willems, S; Witt, H; Zeemering, S; Kirchhof, P.
Longer and better lives for patients with atrial fibrillation: the 9th AFNET/EHRA consensus conference.
Europace. 2024; 26(4):
Doi: 10.1093/europace/euae070
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Scherr Daniel
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- AIMS: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). METHODS AND RESULTS: Eighty-three international experts met in Münster for 2 days in September 2023. Key findings are as follows: (i) Active rhythm management should be part of the default initial treatment for all suitable patients with AF. (ii) Patients with device-detected AF have a low burden of AF and a low risk of stroke. Anticoagulation prevents some strokes and also increases major but non-lethal bleeding. (iii) More research is needed to improve stroke risk prediction in patients with AF, especially in those with a low AF burden. Biomolecules, genetics, and imaging can support this. (iv) The presence of AF should trigger systematic workup and comprehensive treatment of concomitant cardiovascular conditions. (v) Machine learning algorithms have been used to improve detection or likely development of AF. Cooperation between clinicians and data scientists is needed to leverage the potential of data science applications for patients with AF. CONCLUSIONS: Patients with AF and a low arrhythmia burden have a lower risk of stroke and other cardiovascular events than those with a high arrhythmia burden. Combining active rhythm control, anticoagulation, rate control, and therapy of concomitant cardiovascular conditions can improve the lives of patients with AF.
- Find related publications in this database (using NLM MeSH Indexing)
-
Humans - administration & dosage
-
Atrial Fibrillation - complications, diagnosis, epidemiology
-
Stroke - etiology, prevention & control
-
Risk - administration & dosage
-
Hemorrhage - administration & dosage
-
Anticoagulants - therapeutic use
- Find related publications in this database (Keywords)
-
Atrial fibrillation
-
Artificial intelligence
-
Biomarkers
-
Heart failure
-
Atrial cardiomyopathy
-
Cognitive function
-
Dementia
-
Outcomes
-
Quality of care
-
Cost
-
Research
-
Rhythm management
-
Catheter ablation
-
Anticoagulation
-
Bleeding
-
Research priorities
-
Technology
-
Stroke
-
Integrated care
-
Screening
-
AFNET
-
EHRA
-
Guidelines
-
Consensus statement